You have 9 free searches left this month | for more free features.

donor chimerism,

Showing 1 - 25 of 2,961

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Response Rate Trial in Shanghai (Decitabine)

Completed
  • Response Rate
  • Shanghai, Shanghai, China
    Blood & Marrow Transplantation Center, RuiJin Hospital
May 19, 2021

Myeloid Chimerism Trial run by the National Heart, Lung, and Blood Institute (NHLBI) (CliniMACS CD34 Reagent)

Recruiting
  • Myeloid Chimerism
  • CliniMACS CD34 Reagent
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Apr 7, 2022

Cell-Free Nucleic Acids Trial (Cell free DNA analysis)

Not yet recruiting
  • Cell-Free Nucleic Acids
  • Cell free DNA analysis
  • (no location specified)
Jan 27, 2022

Sickle Cell Disease, Beta Thalassemia Trial in New York (Busulfan, Fludarabine, Alemtuzumab)

Active, not recruiting
  • Sickle Cell Disease
  • Beta Thalassemia
  • New York, New York
    Morgan Stanley Children's Hospital, New York-Presbyterian, Colum
Aug 12, 2021

Kidney Transplant Rejection Trial (MDR-103)

Not yet recruiting
  • Kidney Transplant Rejection
  • MDR-103
  • (no location specified)
Apr 4, 2022

MDS, Leukemia, Myeloid, Acute Trial in London (DLI will be administered to all patients at Month 4 (+/- 20 days) after stem cell

Unknown status
  • Myelodysplastic Syndromes
  • Leukemia, Myeloid, Acute
  • DLI will be administered to all patients at Month 4 (+/- 20 days) after stem cell transplant regardless of peripheral blood CD3 chimerism (including if they have full donor chimerism)
  • DLI will be administered from Month 6 (+/- 20 days) after stem cell transplant according to institutional practice
  • London, United Kingdom
    King's College Hospital NHS Foundation Trust
Apr 1, 2020

Waning Donor Chimerism, Waning Immune Function, Primary Immunodeficiency Disease(s) Trial in Cincinnati (CD34+)

Terminated
  • Waning Donor Chimerism
  • +3 more
  • CD34+
  • Cincinnati, Ohio
    Cincinnati Children's Hospital Medical Center
Nov 7, 2019

Graft-versus-host Disease, Poor Graft Function, Low Donor T-cell Chimerism Trial in Belgium, Netherlands (Mesenchymal stem

Recruiting
  • Graft-versus-host Disease
  • +2 more
  • Mesenchymal stem cells
  • Edeghem, Antwerpen, Belgium
  • +11 more
Mar 22, 2022

B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell

Unknown status
  • B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation
  • +4 more
  • Blinatumomab in combination with donor lymphocyte infusion
  • Munich, Germany
    Klinikum der Universität München
Jun 13, 2019

Myeloid Malignancy Trial in Detroit (azacitidine)

Recruiting
  • Myeloid Malignancy
  • Detroit, Michigan
    Henry ford hospital
Dec 23, 2021

Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
    • Brisbane, California
    • +4 more
    Jul 18, 2022

    Adding Azathioprine/Hydroxyurea Preconditioning to

    Recruiting
    • Sickle Cell Disease
    • Preconditioning with azathiprine and hydroxyurea (3 months)
    • Amsterdam, Netherlands
      Amsterdam Medical Centre
    Feb 9, 2022

    Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia Trial in Salt Lake City, Seattle, Torino

    Completed
    • Acute Lymphoblastic Leukemia
    • +9 more
    • Salt Lake City, Utah
    • +4 more
    Jan 15, 2020

    Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid

    Completed
    • Adult Acute Myeloid Leukemia in Remission
    • +16 more
    • iodine I 131 monoclonal antibody BC8
    • +7 more
    • Seattle, Washington
      Fred Hutchinson Cancer Research Center/University of Washington
    Nov 8, 2019

    Sickle Cell Disease Trial in Amsterdam (Engerix-B)

    Recruiting
    • Sickle Cell Disease
    • Amsterdam, Netherlands
      Amsterdam Medical Centre
    Jan 6, 2022

    Beta Thalassemia Major Trial in Nanning (Interleukin-2, Donor Regulatory T-Lymphocytes)

    Unknown status
    • Beta Thalassemia Major
    • Nanning, Guangxi, China
      the First Affiliated Hospital of Guangxi Medical University
    Aug 24, 2018

    Intestinal Transplantation Trial in New York (Cell Therapy)

    Recruiting
    • Intestinal Transplantation
    • Cell Therapy
    • New York, New York
      Columbia University Irving Medical Center/NYP
    Dec 28, 2021

    Primary Immune Deficiency Disorders, Metabolic Disease Trial in Saint Petersburg (Haploidentical Hematopoietic Cell

    Recruiting
    • Primary Immune Deficiency Disorders
    • Metabolic Disease
    • Haploidentical Hematopoietic Cell Transplantation
    • Saint Petersburg, Florida
      Johns Hopkins All Children's Hospital
    Sep 9, 2021

    Idiopathic Aplastic Anemia, Severe Aplastic Anemia, Moderate Aplastic Anemia Requiring Transfusions Trial (HSCT Arm group)

    Not yet recruiting
    • Idiopathic Aplastic Anemia
    • +2 more
    • HSCT Arm group
    • (no location specified)
    Jun 10, 2022

    Acute Myeloid Leukaemia (AML), MDS (MDS) Trial in Germany, Netherlands (Panobinostat)

    Active, not recruiting
    • Acute Myeloid Leukaemia (AML)
    • Myelodysplastic Syndromes (MDS)
    • Stuttgart, Baden-Württemberg, Germany
    • +18 more
    Dec 13, 2021

    Kidney Transplant Rejection Trial (MDR-102, Immunosuppressive Agents)

    Not yet recruiting
    • Kidney Transplant Rejection
    • MDR-102
    • Immunosuppressive Agents
    • (no location specified)
    Apr 4, 2022

    Non-Malignant Tumor Trial in Seattle (biological, drug, radiation, procedure)

    Recruiting
    • Non-Malignant Neoplasm
    • Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
    • +7 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Feb 25, 2022

    Sickle Cell Disease Trial in Louisville, Durham, Pittsburgh (Enriched Hematopoetic Stem Cell Infusion)

    Completed
    • Sickle Cell Disease
    • Enriched Hematopoetic Stem Cell Infusion
    • Louisville, Kentucky
    • +2 more
    Oct 6, 2020

    Severe Combined Immune Deficiency (SCID) Trial run by the National Institute of Allergy and Infectious Diseases (NIAID)

    Enrolling by invitation
    • Severe Combined Immune Deficiency (SCID)
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Aug 24, 2022

    Sickle Cell Disease, Hemoglobinopathies Trial in Nashville (drug, procedure, radiation)

    Active, not recruiting
    • Sickle Cell Disease
    • Hemoglobinopathies
    • Nashville, Tennessee
      Vanderbilt-Ingram Cancer Center
    Dec 20, 2021